Has Michael Ozier received payments from drug or device companies?

Yes. Drug and device makers reported $6,032 in general payments to Michael Ozier across 400 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Ozier did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Ozier come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Ozier

Family Medicine · New Braunfels, TXNPI 1093793135

Payments from drug & device makers

$6,032in general payments, 2019–2025

Across 400 payments — averaging $15.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$981
Lilly USA, LLC$768
AbbVie$516
Boehringer Ingelheim$432
Sanofi-aventis U.S. LLC$404
AstraZeneca$370
plus $3K from 34 others

What the payments were for

Food & beverage$6,024100%
Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	80	$981
Lilly USA, LLC	75	$768
AbbVie(2 entities)	27	$516
Boehringer Ingelheim	26	$432
Sanofi-aventis U.S. LLC	25	$404
AstraZeneca	21	$370
GSK	17	$321
SK Life Science, Inc.	12	$259
Novartis	15	$242
Pfizer	10	$174
Amarin Pharma, Inc.	10	$173
Bayer	10	$169
Merck	11	$165
Amgen(2 entities)	9	$161
Biogen	9	$157
Biohaven Pharmaceuticals, Inc.	6	$95
Lundbeck LLC	5	$92
Biohaven Pharmaceutical Holding Company Ltd.	3	$50
GE HealthCare	2	$41
Neurocrine Biosciences, Inc.	2	$39
Eisai Inc.	2	$36
Supernus Pharmaceuticals, Inc.	2	$34
Aquestive Therapeutics, Inc.	2	$33
Avanir Pharmaceuticals, Inc.	2	$30
Corium, LLC	1	$26
EMD Serono, Inc.	1	$25
Jazz Pharmaceuticals Inc.	1	$25
Teva Pharmaceuticals USA, Inc.	2	$24
Astellas Pharma US Inc	1	$21
Argenx US, Inc.	1	$21
IBSA Pharma Inc.	1	$20
Neurelis, Inc.	1	$18
Idorsia Pharmaceuticals US Inc	1	$15
Esperion Therapeutics, Inc.	1	$15
Genentech USA, Inc.	1	$14
EUSA Pharma (US) LLC	1	$14
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$14
Takeda Pharmaceuticals U.S.A., Inc.	1	$13
Kyowa Kirin, Inc.	1	$12
Currax Pharmaceuticals LLC	1	$12

How this compares

$6,032 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Metoprolol Succinate	21	$572
Atorvastatin Calcium	27	$252
Pantoprazole Sodium	14	$243
Montelukast Sodium	22	$201
Levothyroxine Sodium	21	$176
Lisinopril	16	$163
Amlodipine Besylate	21	$133
Losartan Potassium	25	$131
Citalopram HbrCitalopram Hydrobromide	14	$74
Metformin Hcl	12	$56

Paid to pharmacies, not to this prescriber.

Other family medicine in New Braunfels

Douglas DenhamSan Antonio$68.5M
Vicki MillerPasadena$58.3M
Hareshkumar BogharaDesoto$30.3M
Earl MartinTomball$30.1M
Lisa HollowayHouston$30.1M
William SegerFort Worth$27.5M
Veronica FragosoHouston$24.5M
Joel SolisMcAllen$21.1M
George AtieeSan Antonio$19.9M
Bonnie ColvilleHouston$19.6M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →